Cargando…

Altered Gut Microbiome in Patients With Dermatomyositis

OBJECTIVE: The study objective was to compare the microbial composition of patients with dermatomyositis (DM) and healthy controls (HCs) and determine whether microbial alterations are associated with clinical manifestations of DM. METHODS: The 16S ribosomal RNA gene sequencing was performed on feca...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Sangmee Sharon, Dong, Tien S., Wang, Jennifer, Lagishetty, Venu, Katzka, William, Jacobs, Jonathan P., Charles‐Schoeman, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374048/
https://www.ncbi.nlm.nih.gov/pubmed/35615912
http://dx.doi.org/10.1002/acr2.11436
_version_ 1784767711405932544
author Bae, Sangmee Sharon
Dong, Tien S.
Wang, Jennifer
Lagishetty, Venu
Katzka, William
Jacobs, Jonathan P.
Charles‐Schoeman, Christina
author_facet Bae, Sangmee Sharon
Dong, Tien S.
Wang, Jennifer
Lagishetty, Venu
Katzka, William
Jacobs, Jonathan P.
Charles‐Schoeman, Christina
author_sort Bae, Sangmee Sharon
collection PubMed
description OBJECTIVE: The study objective was to compare the microbial composition of patients with dermatomyositis (DM) and healthy controls (HCs) and determine whether microbial alterations are associated with clinical manifestations of DM. METHODS: The 16S ribosomal RNA gene sequencing was performed on fecal samples from patients with DM and HCs. Microbial composition and diversity were compared between subjects with DM and HCs and in association with several DM‐specific clinical variables, including myositis‐specific autoantibodies (MSAs). Differentially abundant microbial taxa and genes associated with clinical characteristics were identified, and functional analysis was performed using predicted metagenomics. Dietary intake was assessed using a 24‐hour dietary recall. RESULTS: The fecal microbiome of 36 patients with DM and 26 HCs were analyzed. Patients with DM trended toward lower microbial diversity compared with HCs. The higher physician global damage score was significantly correlated with the lower microbial diversity in patients with DM. Patients with interstitial lung disease (ILD)‐associated MSA (antisynthetase antibody (ab), anti‐melanoma differentiation‐associated protein 5 ab, n = 12) had significant differences in microbial composition and lower microbial diversity compared with HCs. Differential abundance testing demonstrated a unique taxonomic signature in the ILD‐MSA subgroup, and predictive metagenomics identified functional alterations in a number of metabolic pathways. A significant increase in the relative abundance of Proteobacteria was positively correlated with multiple pathways involved in lipopolysaccharide synthesis and transport in the ILD‐MSA group. CONCLUSION: Patients with DM, particularly with ILD‐associated MSAs, have lower microbial diversity and a distinct taxonomic composition compared with HCs. Further studies are needed to validate our findings and elucidate specific pathogenetic mechanisms that link the gut microbiome to clinical and pathological features of DM.
format Online
Article
Text
id pubmed-9374048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-93740482022-08-16 Altered Gut Microbiome in Patients With Dermatomyositis Bae, Sangmee Sharon Dong, Tien S. Wang, Jennifer Lagishetty, Venu Katzka, William Jacobs, Jonathan P. Charles‐Schoeman, Christina ACR Open Rheumatol Original Articles OBJECTIVE: The study objective was to compare the microbial composition of patients with dermatomyositis (DM) and healthy controls (HCs) and determine whether microbial alterations are associated with clinical manifestations of DM. METHODS: The 16S ribosomal RNA gene sequencing was performed on fecal samples from patients with DM and HCs. Microbial composition and diversity were compared between subjects with DM and HCs and in association with several DM‐specific clinical variables, including myositis‐specific autoantibodies (MSAs). Differentially abundant microbial taxa and genes associated with clinical characteristics were identified, and functional analysis was performed using predicted metagenomics. Dietary intake was assessed using a 24‐hour dietary recall. RESULTS: The fecal microbiome of 36 patients with DM and 26 HCs were analyzed. Patients with DM trended toward lower microbial diversity compared with HCs. The higher physician global damage score was significantly correlated with the lower microbial diversity in patients with DM. Patients with interstitial lung disease (ILD)‐associated MSA (antisynthetase antibody (ab), anti‐melanoma differentiation‐associated protein 5 ab, n = 12) had significant differences in microbial composition and lower microbial diversity compared with HCs. Differential abundance testing demonstrated a unique taxonomic signature in the ILD‐MSA subgroup, and predictive metagenomics identified functional alterations in a number of metabolic pathways. A significant increase in the relative abundance of Proteobacteria was positively correlated with multiple pathways involved in lipopolysaccharide synthesis and transport in the ILD‐MSA group. CONCLUSION: Patients with DM, particularly with ILD‐associated MSAs, have lower microbial diversity and a distinct taxonomic composition compared with HCs. Further studies are needed to validate our findings and elucidate specific pathogenetic mechanisms that link the gut microbiome to clinical and pathological features of DM. Wiley Periodicals, Inc. 2022-05-26 /pmc/articles/PMC9374048/ /pubmed/35615912 http://dx.doi.org/10.1002/acr2.11436 Text en © 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Bae, Sangmee Sharon
Dong, Tien S.
Wang, Jennifer
Lagishetty, Venu
Katzka, William
Jacobs, Jonathan P.
Charles‐Schoeman, Christina
Altered Gut Microbiome in Patients With Dermatomyositis
title Altered Gut Microbiome in Patients With Dermatomyositis
title_full Altered Gut Microbiome in Patients With Dermatomyositis
title_fullStr Altered Gut Microbiome in Patients With Dermatomyositis
title_full_unstemmed Altered Gut Microbiome in Patients With Dermatomyositis
title_short Altered Gut Microbiome in Patients With Dermatomyositis
title_sort altered gut microbiome in patients with dermatomyositis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374048/
https://www.ncbi.nlm.nih.gov/pubmed/35615912
http://dx.doi.org/10.1002/acr2.11436
work_keys_str_mv AT baesangmeesharon alteredgutmicrobiomeinpatientswithdermatomyositis
AT dongtiens alteredgutmicrobiomeinpatientswithdermatomyositis
AT wangjennifer alteredgutmicrobiomeinpatientswithdermatomyositis
AT lagishettyvenu alteredgutmicrobiomeinpatientswithdermatomyositis
AT katzkawilliam alteredgutmicrobiomeinpatientswithdermatomyositis
AT jacobsjonathanp alteredgutmicrobiomeinpatientswithdermatomyositis
AT charlesschoemanchristina alteredgutmicrobiomeinpatientswithdermatomyositis